A Phase 2 Study of XL184 (Cabozantinib) in Treating Patients With Relapsed Osteosarcomas and Ewing Sarcomas
Phase of Trial: Phase II
Latest Information Update: 30 May 2017
At a glance
- Drugs Cabozantinib (Primary)
- Indications Ewing's sarcoma; Osteosarcoma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 10 Mar 2017 Planned primary completion date changed from 1 Jun 2016 to 1 Jul 2017.
- 01 Nov 2016 Status changed from recruiting to suspended.